Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 03:00 ET | Source: Onco3R Therapeutics BV

Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium

Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2...
October 13, 2025 07:59 ET | Source: Research and Markets

Conjugated Drugs (XDCs) in Oncology Market Intelligence Tool Launched – Covering 2,500+ Pipeline Drugs and 1,300+ Funding Rounds

Dublin, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Market of Conjugated Drugs (XDCs) in Oncology with Confidence" directory has been added to ...
October 13, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Appoints Annette Breunig as Chief People Officer

Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies...
October 01, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States

Basel, Switzerland / Munich, Germany, October 01, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it...
September 30, 2025 08:40 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first...
September 25, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
September 22, 2025 04:32 ET | Source: Research and Markets

Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030: Advances in Next-Gen Immunotherapies, AI, and Biomarker-Driven Personalization are Driving Transformational Growth

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The revenue...
September 16, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...
September 11, 2025 09:17 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi)...
September 11, 2025 07:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further...